The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
Palakurthi et al.
Cancer Immunology Research
July 2019
Authors and Affiliates
Palakurthi S#1, Kuraguchi M#1, Zacharek SJ#1, Zudaire E#2, Huang W1, Bonal DM3, Liu J1, Dhaneshwar A1, DePeaux K1, Gowaski MR1, Bailey D1, Regan SN1, Ivanova E1, Ferrante C2, English JM1, Khosla A4, Beck AH4, Rytlewski JA5, Sanders C5, Laquerre S2, Bittinger MA1, Kirschmeier PT1, Packman K2, Janne PA1,6, Moy C2, Wong KK1,7, Verona RI#8, Lorenzi MV8;
1
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
2
Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania.
3
Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
4
PathAI, Boston, Massachusetts.
5
Adaptive Biotechnologies, Seattle, Washington.
6
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
7
Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, New York.
8
Janssen, Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania. rverona@its.jnj.com mlorenzi@its.jnj.com.
#
Contributed equally